university of texas, snoept is in the minority.elievers by harvard doctors are convenned by genetic data linkening amyloids to alzheimer's. >> i think scientists are reading the leicester carefully, paying attention to all the details for the last 30 years while the journey of the hypothesis would have to come to only one conclusion. and that is that the trial has failed the hypothesis. >> reporter: trial failures that most recently included one from merck in february and eli lilly in november. litt lily spent more than $2 million in two decades, many believe those failures may have been due to timing. >> what we've realized in alzheimer's disease is that the disease process itself in the brain begins you know somewhere between ten and 20 years actually before. if you wait too late. if you are treating patients who are already severely impaired, cognitively, it's probably too late to be treating them with the kinds of treatments we are now using. >> reporter: ongoing work from biogen, merck and others is still targeting amyloid. ea